But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
Ebola stocks have soared in recent weeks but a closer look at fundamentals may serve as a reality check for investors playing the story.
As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Given the usual hype surrounding small-cap biotechs, Brainstorm CEO Tony Fiorino is refreshingly candid about the company's chances of developing a stem-cell treatment to counter ALS symptoms.
U.S. patients suffering from idiopathic pulmonary fibrosis finally gain access to Esbriet, approved for use in Europe since early 2011.
It's one thing for small-cap biotech stocks to trade horribly, but healthcare investors take notice when shares of Gilead Sciences GILD take a turn south.
Health care investors can be divided into two camps with respect to Sarepta: Those who believe eteplirsen is effective against DMD and those who don't.